BioStock: Bioinvent shifts into higher gear

The news of BioInvent's BI-1206 advancement to the expansion phase of the phase I/IIa study in the Non-Hodgkin's Lymphoma following an end-of-phase I meeting with the FDA, crowns an eventful spring for the company. Among other things, a milestone payment has been received from Hope Medicine following clinical advancements for an out-licensed antibody. It has also had three poster presentations at the AACR American Association for Cancer Research Annual Meeting, while a fifth development programme will soon enter the clinical phase.

Read the full article about BioInvent at biostock.se:

https://www.biostock.se/en/2022/05/bioinvent-shifts-into-higher-gear/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/